Hikma Pharmaceuticals PLC (LON:HIK)

Market Cap	2.90B -32.0%
Revenue (ttm)	2.49B +7.1%
Net Income	298.69M +12.0%
EPS	1.34 +12.4%
Shares Out	216.11M
PE Ratio	9.99
Forward PE	8.09
Dividend	0.62 (4.62%)
Ex-Dividend Date	Mar 19, 2026

Volume	566,065
Average Volume	1,302,518
Open	1,350.00
Previous Close	1,348.00
Day's Range	1,339.50 - 1,362.50
52-Week Range	1,187.00 - 2,164.00
Beta	0.61
RSI	56.12
Earnings Date	May 7, 2026

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 9,400
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HIK

Financial Performance

In 2025, Hikma Pharmaceuticals's revenue was $3.35 billion, an increase of 7.10% compared to the previous year's $3.13 billion. Earnings were $402.00 million, an increase of 11.98%.

Financial numbers in USD